When kidney cancer has spread beyond the organ itself to distant parts of the body such as the lungs, bones, or brain, doctors call it metastatic renal cell carcinoma. This advanced stage of kidney cancer presents unique challenges, but ongoing medical advances and a range of treatment approaches are helping patients manage symptoms, slow disease progression, and maintain quality of life for as long as possible.

Understanding Treatment Goals for Advanced Kidney Cancer

When renal cell carcinoma reaches the metastatic stage, the focus of medical care shifts in important ways. Unlike early-stage kidney cancer that may be cured through surgery, metastatic kidney cancer is generally not curable with current treatments. However, this does not mean that effective treatment options are absent. The primary goals become controlling the spread of cancer, managing symptoms to help patients feel as comfortable as possible, and extending survival time while maintaining a good quality of life.

Treatment decisions depend heavily on several individual factors. Your doctor will consider where the cancer has spread in your body, how quickly it appears to be growing, your overall health status, how well your remaining kidney is functioning, and your personal preferences regarding treatment. Some people with metastatic kidney cancer may have slow-growing disease that allows for a period of careful monitoring before starting aggressive treatment. Others may need to begin treatment immediately.

Medical societies and cancer organizations have developed standard treatment approaches based on years of research and clinical experience with thousands of patients. At the same time, researchers around the world are actively testing new therapies in clinical trials. These studies explore innovative drugs and treatment combinations that may offer better results than current standard options. Participation in clinical trials gives some patients access to promising new treatments before they become widely available.

The landscape of metastatic kidney cancer treatment has changed dramatically over the past two decades. Therapies that work with the immune system and drugs that target specific cancer cell pathways have largely replaced older treatments that were less effective and caused more severe side effects. Understanding your options, including both standard treatments and experimental approaches being tested in clinical trials, can help you and your medical team make informed decisions about your care.

Standard Treatment Approaches for Metastatic Renal Cell Carcinoma

The foundation of treatment for metastatic kidney cancer typically involves systemic therapies—medicines that travel throughout the body to reach cancer cells wherever they may be. These treatments work differently than surgery, which removes cancer from a specific location. The most commonly used systemic treatments fall into two main categories: targeted therapies and immunotherapies.

Targeted therapy drugs work by interfering with specific molecules that cancer cells need to grow and spread. One major group of targeted therapies focuses on vascular endothelial growth factor, or VEGF. This protein helps tumors build their own blood supply, which they need to grow larger. By blocking VEGF or the receptors it attaches to, these drugs essentially starve the tumor by cutting off its blood flow. Commonly used VEGF-targeting drugs include sunitinib, which is often the first choice, along with pazopanib, sorafenib, cabozantinib, and axitinib. These medications are typically taken as pills at home.

Another group of targeted therapies works on a protein called mammalian target of rapamycin, or mTOR. This protein helps control how cells grow and divide. Drugs that block mTOR, including temsirolimus and everolimus, can slow cancer growth. Sometimes doctors prescribe a combination of different targeted therapies—for example, lenvatinib combined with everolimus—particularly if cancer has stopped responding to previous VEGF-blocking treatments.

Your doctor will consider many factors when choosing which targeted therapy to recommend. These include the specific type of kidney cancer you have, which treatments you may have received before, and your prognostic factors. Medical teams often use a system called the International Metastatic Renal Cell Carcinoma Database Consortium classification, or IMDC, to categorize patients into favorable-risk, intermediate-risk, or poor-risk groups. This classification looks at six factors including the time from diagnosis to when systemic treatment starts, your performance status (how well you can carry out daily activities), and certain blood test results including hemoglobin, calcium, neutrophils, and platelets. Your risk group helps guide which treatments are most likely to help you.

Immunotherapy represents another major treatment approach. These medications work by helping your own immune system recognize and attack cancer cells more effectively. Checkpoint inhibitors are the most commonly used type of immunotherapy for kidney cancer. They work by blocking proteins that normally act as brakes on the immune system. When these brakes are released, immune cells called T-cells can mount a stronger attack against cancer. Nivolumab, which targets a checkpoint protein called PD-1, is approved for metastatic kidney cancer, particularly when cancer no longer responds to VEGF-blocking drugs. Ipilimumab, which targets a different checkpoint protein called CTLA-4, is sometimes combined with nivolumab. Avelumab is another checkpoint inhibitor that may be used.

Many doctors now prescribe combinations of targeted therapy and immunotherapy together as first-line treatment. For example, pembrolizumab combined with axitinib, or avelumab combined with axitinib, may be more effective than either drug alone. For patients in the favorable-risk group, sunitinib or pazopanib alone might still be reasonable options. The combination of nivolumab and ipilimumab has shown particularly good results in certain patient groups.

Surgery still plays an important role even in metastatic disease. If you are healthy enough for an operation, your surgeon might perform a cytoreductive nephrectomy—removing the kidney that contains the main tumor along with as much cancer as can be safely taken out. Research suggests this surgery may help targeted therapies work better and could improve survival. In selected cases where cancer has spread to just one or two other locations, such as a single lung nodule or brain metastasis, surgery to remove those spots might also be considered.

The duration of treatment varies widely. Some people continue taking targeted therapy or immunotherapy for many months or even years as long as it is working and side effects remain manageable. Others may need to switch treatments if cancer progresses or side effects become too severe. Regular monitoring through imaging scans and blood tests helps your doctor know whether treatment is working.

Side effects are an important consideration with any cancer treatment. Targeted therapies commonly cause high blood pressure, diarrhea, fatigue, hand-foot syndrome (redness and pain on palms and soles), loss of appetite, and changes in taste. Blood tests may show low thyroid function or decreased blood cell counts. Immunotherapies can cause different side effects because they activate the immune system. These may include fatigue, rash, itching, diarrhea, and in some cases, inflammation of organs like the lungs, liver, intestines, or thyroid gland. Some immune-related side effects can be serious and require prompt treatment with steroids to calm the immune response.

Your medical team will monitor you closely during treatment and can provide medications or other interventions to manage side effects. It is crucial to report any new symptoms immediately rather than waiting until your next scheduled appointment. Many side effects can be controlled effectively if caught early, allowing you to continue beneficial treatment.

In addition to systemic therapies, radiation therapy may be used to treat specific areas where cancer has spread. This is particularly common when cancer reaches the bones or brain. Radiotherapy uses high-energy rays to kill cancer cells in a targeted area. While it does not eliminate cancer throughout the body, it can effectively control symptoms such as pain from bone metastases or neurological problems from brain metastases. Some preliminary research suggests that a specialized, highly focused form of radiation called stereotactic body radiotherapy might have a role in treating kidney cancer, although this is still being studied.

Older forms of immunotherapy called cytokines—specifically interleukin-2 and interferon-alpha—were once commonly used for metastatic kidney cancer. These immune-stimulating proteins can cause tumors to shrink in about 10 to 20 percent of patients. However, they cause severe side effects including flu-like symptoms, fatigue, and potentially dangerous drops in blood pressure. Because newer immunotherapies and targeted drugs work better with fewer severe side effects, cytokines are now used only in rare circumstances when other treatments have failed.

Innovative Treatments Being Tested in Clinical Trials

While standard treatments have improved outcomes for many patients with metastatic kidney cancer, researchers continue searching for even better approaches. Clinical trials test new drugs, new combinations of existing drugs, and entirely novel treatment strategies. Participating in a clinical trial may give you access to cutting-edge therapies that could potentially be more effective than currently available options.

Clinical trials follow a structured process with three main phases. Phase I trials primarily focus on safety—determining what dose of a new drug can be given safely and what side effects occur. These trials typically involve small numbers of patients who have already tried multiple other treatments. Phase II trials begin to assess whether the treatment actually works against cancer. They look at how many patients respond to treatment and how long responses last. Phase III trials compare the new treatment against the current standard treatment in large groups of patients. These trials provide the strongest evidence about whether a new treatment is better than what is already available.

Several types of innovative treatments are currently being studied in clinical trials for metastatic kidney cancer. Researchers are testing new checkpoint inhibitors that target different immune pathways. For example, drugs targeting a checkpoint protein called LAG-3 or another called TIM-3 are being evaluated, sometimes in combination with existing PD-1 or CTLA-4 inhibitors. The goal is to release even more brakes on the immune system to generate a stronger anti-cancer response.

Another active area of research involves new targeted therapies. Scientists are developing drugs that block different molecules involved in cancer cell growth and survival. Some experimental drugs target the HIF pathway, which cancer cells use to survive in low-oxygen conditions. Others target different parts of the mTOR pathway or cell cycle checkpoints that regulate when cells divide. Researchers are also studying combinations of multiple targeted drugs together or combinations of targeted drugs with immunotherapy to see if attacking cancer through multiple mechanisms simultaneously works better than current approaches.

Cell-based therapies represent an exciting frontier in cancer treatment. In this approach, immune cells are removed from a patient’s body, modified or multiplied in the laboratory, and then infused back into the patient to fight cancer. CAR T-cell therapy, which has shown remarkable success in certain blood cancers, is being adapted and tested for kidney cancer. In CAR T-cell therapy, T-cells are genetically engineered to express special receptors that help them recognize and attack cancer cells. While this technology is still experimental for kidney cancer, early studies are exploring whether it can be effective.

Tumor-infiltrating lymphocyte therapy, or TIL therapy, is another cell-based approach. This involves isolating immune cells that have already traveled into the tumor, growing large numbers of them in the lab, and giving them back to the patient. These cells have already demonstrated some ability to recognize the cancer, and expanding their numbers might enhance the immune attack.

Cancer vaccines are also being investigated. Unlike vaccines that prevent infections, cancer vaccines are designed to teach the immune system to recognize cancer cells as foreign invaders. Some vaccines use pieces of proteins found on kidney cancer cells, while others use killed tumor cells or viruses that have been modified to carry cancer-associated proteins. The goal is to trigger a strong, lasting immune response against the cancer.

Researchers are exploring whether drugs that target cancer metabolism might be useful. Cancer cells often have different metabolic needs than normal cells—they consume nutrients differently and produce different waste products. Drugs that interfere with cancer-specific metabolic pathways could potentially slow tumor growth while sparing normal cells.

Some trials are studying whether treating patients earlier with immunotherapy—immediately after surgery for high-risk localized kidney cancer—can prevent or delay the development of metastases. This is called adjuvant therapy. If cancer cells have already started to spread but cannot yet be detected on scans, treating them early might improve long-term outcomes.

Clinical trials for metastatic kidney cancer are conducted at cancer centers around the world, including sites in the United States, Canada, Europe, and other regions. Eligibility requirements vary by trial but typically include factors such as the type and stage of your cancer, previous treatments you have received, your overall health status, and results of specific laboratory tests. Your oncologist can help you search for trials that might be appropriate for you, or you can search clinical trial databases online.

While clinical trials offer potential benefits, they also involve uncertainties. A new treatment being tested may not work better than standard treatment, and it might cause unexpected side effects. However, all participants in clinical trials receive careful monitoring, and trials are designed with multiple safeguards to protect patient safety. Additionally, even if you do not personally benefit from a trial, your participation helps advance medical knowledge and may help future patients.

Most Common Treatment Methods

• Targeted Therapy
  • VEGF-blocking drugs such as sunitinib, pazopanib, sorafenib, cabozantinib, and axitinib that interfere with tumor blood vessel formation
  • mTOR inhibitors including temsirolimus and everolimus that block proteins controlling cell growth and division
  • Tyrosine kinase inhibitors like lenvatinib that block signals helping cells grow and form new blood vessels
  • Usually taken as pills at home on a daily or intermittent schedule
  • Choice depends on risk classification, prior treatments, and individual patient factors
• Immunotherapy
  • Checkpoint inhibitors such as nivolumab, ipilimumab, pembrolizumab, and avelumab that release brakes on the immune system
  • May be used alone or in combination with other immunotherapy or targeted therapy drugs
  • Administered as intravenous infusions at regular intervals, typically every two to three weeks
  • Older cytokine therapies (interleukin-2 and interferon-alpha) rarely used now due to severe side effects
• Surgery
  • Cytoreductive nephrectomy removes the kidney containing the primary tumor and as much cancer as possible
  • May improve response to systemic therapies when performed before starting targeted therapy or immunotherapy
  • Sometimes used to remove isolated metastases in the lung, brain, or other locations
  • Reserved for patients healthy enough to tolerate the operation
• Radiation Therapy
  • High-energy rays used to kill cancer cells in specific areas where cancer has spread
  • Commonly used for bone metastases causing pain or brain metastases causing neurological symptoms
  • Stereotactic body radiotherapy (SBRT) delivers highly focused radiation in fewer treatments
  • Helps control symptoms and prevent complications from metastases
• Combination Treatments
  • Pairing checkpoint inhibitors with VEGF-targeting drugs (such as pembrolizumab plus axitinib or avelumab plus axitinib)
  • Combining two immunotherapy drugs (nivolumab plus ipilimumab)
  • Increasingly used as first-line treatment based on risk stratification

Living With Metastatic Kidney Cancer

Beyond medical treatments, many aspects of daily life impact how you feel when living with metastatic kidney cancer. Taking an active role in your own care through healthy lifestyle choices, symptom management, and emotional support can make a significant difference in your quality of life.

Nutrition plays an important supporting role. Eating a well-balanced diet with plenty of fruits and vegetables, whole grains, and lean proteins helps maintain your strength, supports your immune system, and may help your body better tolerate treatment. If you have had a kidney removed or if your remaining kidney is not functioning optimally, you may need to follow specific dietary guidelines. Your doctor or a registered dietitian can provide personalized recommendations about protein intake, sodium, potassium, phosphorus, and fluid consumption based on your kidney function.

Physical activity, even in small amounts, can improve energy levels, mood, and overall well-being. Many people with metastatic cancer assume they should rest completely, but research shows that appropriate exercise actually helps reduce fatigue rather than worsening it. The key is finding activities that match your current energy level and physical abilities. Walking, gentle yoga, swimming, or simply doing light household tasks can all count as beneficial movement. Always discuss exercise plans with your doctor, especially if cancer has spread to your bones, as certain activities might need to be modified or avoided.

Managing symptoms effectively requires open communication with your healthcare team. Common symptoms of metastatic kidney cancer include fatigue, pain, blood in the urine, loss of appetite, unintended weight loss, and night sweats. Symptoms can also arise from where cancer has spread—bone pain from skeletal metastases, shortness of breath from lung metastases, or headaches from brain metastases. Never assume that worsening symptoms are just something you must endure. Many symptoms can be controlled with medications, physical therapy, nutritional support, or other interventions.

Keeping a symptom diary can help you and your doctor identify patterns and triggers. Note when symptoms occur, how severe they are, what you were doing at the time, and what makes them better or worse. This information helps your medical team adjust your treatment plan and prescribe appropriate symptom relief measures.

Sleep quality often suffers during cancer treatment due to anxiety, medication side effects, pain, or other factors. Good sleep hygiene practices can help—maintaining regular sleep and wake times, creating a comfortable sleep environment, avoiding caffeine late in the day, and establishing a calming bedtime routine. If sleep problems persist, talk to your doctor. Medications or other interventions might be appropriate.

Emotional and mental health deserve as much attention as physical symptoms. Receiving a diagnosis of metastatic cancer is frightening and can trigger anxiety, depression, anger, or a sense of loss. These feelings are normal responses to a serious illness. Many people find it helpful to talk with a counselor, psychologist, or social worker who specializes in helping cancer patients. Support groups, whether in person or online, connect you with others who truly understand what you are going through. Some people find comfort in spiritual or religious support. Others prefer to confide in close friends or family members.

Palliative care teams specialize in improving quality of life for people with serious illnesses. Importantly, palliative care is not the same as hospice care or end-of-life care. Palliative care can be provided at any stage of cancer, even while you are receiving active treatment aimed at controlling the disease. Palliative care specialists work alongside your oncology team to address physical symptoms, emotional distress, and practical concerns. They can help coordinate care among different specialists, ensure your symptoms are well controlled, and support you and your family in making difficult decisions.

Practical matters also require attention. Metastatic cancer and its treatment can be expensive, and managing medical bills, insurance issues, and time away from work creates additional stress. Social workers at your cancer center can help connect you with financial assistance programs, transportation services, and other resources. Do not hesitate to ask for help—these services exist specifically to support patients and families dealing with cancer.

Family members and close friends often struggle with their own feelings of helplessness, fear, and grief. They want to help but may not know what to do. Being clear about your needs and preferences—whether you want company or solitude, help with specific tasks, or just someone to listen—makes it easier for loved ones to provide meaningful support. Including family in appointments with your healthcare team, if you are comfortable doing this, helps ensure everyone understands your medical situation and treatment plan.

Although metastatic kidney cancer is generally not curable with current treatments, many people live for years with their disease well controlled. Some experience long periods where cancer remains stable or even shrinks. Treatment advances over the past two decades have significantly improved outcomes, and research continues to bring new options. Staying engaged with your medical care, taking care of yourself physically and emotionally, and maintaining hope while also being realistic about your situation can help you make the most of each day.